在帕金森病中结步伐的按需排队:一项随机对照试验
Demi Zoetewei1, Talia Herman2, Pieter Ginis1
1KU Leuven, Department of Rehabilitation Sciences, Neurorehabilitation Research Group (eNRGy), Leuven, Belgium.
概括
在积极使用时,DeFOG系统有效地减少了帕金森病 (PD) 患者的步态结 (FOG). 每天使用4周没有显示组益处,但立即使用显著减轻FOG.
科学领域:
- 神经学 神经学
- 生物医学工程 生物医学工程
- 康复科学 康复科学 康复科学
背景情况:
- 听觉暗示可以帮助管理帕金森病 (PD) 的步态结 (FOG).
- 随着时间的推移,持续的提示可能会降低有效性.
- 在检测FOG事件时,DeFOG系统提供个性化,按需的听觉线索.
研究的目的:
- 评估DeFOG系统在减少FOG时的有效性.
- 在每天使用4周后评估效果,与活跃对照组对比.
- 确定在不同药物状态下使用DeFOG的直接影响.
主要方法:
- 一项随机对照试验,涉及63名患有PD和每日FOG的个人.
- 将DeFOG系统与接受步数反的活跃对照组进行比较.
- 视频评级FOG严重程度通过家庭FOG诱导协议评估,无论是用药还是不用药,以及使用/不使用DeFOG.
主要成果:
- 在4周后,FOG严重程度在组间没有显著差异.
- 在组内分析显示,DeFOG显著减轻了FOG (d=0.57),无论药物状态如何.
- 联合使用DeFOG和药物显示出更大的效果大小 (d=0.67).
结论:
- 在严重的PD患者中,DeFOG系统显著减少了FOG,无论是服用药物还是不服用药物.
- 每天使用DeFOG四周,除非系统被积极佩戴,否则在协议期间FOG没有改善.
- 按需提示,就像其他行走辅助工具一样,只有在使用时才有效.
更多相关视频
06:21Postural Organization of Gait Initiation for Biomechanical Analysis Using Force Platform Recordings
Published on: July 26, 2022
2.5K
06:25Paw-Print Analysis of Contrast-Enhanced Recordings PrAnCER: A Low-Cost, Open-Access Automated Gait Analysis System for Assessing Motor Deficits
Published on: August 12, 2019
8.5K
相关概念视频
01:24Parkinson's Disease: Treatment
264
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
264
01:15Parkinson's Disease: Overview
541
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
541